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Department for Vascular Medicine, Heart Center at University Medical Center Hamburg-Eppendorf, Hamburg, GermanyWhen Wilson and Jungner1 wrote their World Health Or-
ganization thesis on “principles and practice for screening of
disease”, they probably were not aware of the landmark
they had set. Although there had been, for a number of
years, an increasing interest among both the medical pro-
fession and the public in disease screening, it was still at a
very early and comparatively primitive stage in the sys-
tematic detection and treatment of early disease. The
central idea of early disease detection and treatment is
simple in principle only. Identifying those requiring treat-
ment for a previously undetected disease and avoiding
harm in those not in need of treatment is a challenging
task! To select diseases suitable for early screening, Wilson
and Jungner developed 10 criteria:1
1. The condition sought should be an important health
problem
2. There should be an accepted treatment for patients
with the recognized disease
3. Facilities for diagnosis and treatment should be
available
4. There should be a recognizable latent or early
symptomatic stage
5. There should be a suitable test or examination
6. The test should be acceptable to the population
7. The natural history of the condition, including
development from latent to declared disease, should
be adequately understood
8. There should be an agreed policy on whom to treat as
patients
9. The cost of case-ﬁnding (including diagnosis and
treatment of patients diagnosed) should be
economically balanced in relation to possible
expenditure on medical care as a whole
10. Case-ﬁnding should be a continuing process and not a
“once and for all” project.
More than 45 years later, the human genome has been
sequenced, and, as a consequence, numerous diseases can
now be identiﬁed at a preclinical stage. This and other
reasons led to the claim of cost-effectiveness in setting up
screening programs.2 Although initially already addressed
by Wilson and Jungner,1 it has now become very obviousDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.02.004
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numerous countries have established screening programs
for many diseases, including cancer (cervical, breast, pros-
tate, and colorectal cancers) and cardiovascular diseases.
Every one of these programs is surrounded by controversy,
not only because the interpretation of data on beneﬁts and
harms is not straightforward, but also because of the vested
interests, as screening is a proﬁtable business. The enthu-
siasm for early detection and prevention of disease is based
on the assumption that it is more cost-effective than
treatment of the disease itself.4 However, for many of the
preventive medical evaluations of healthy individuals,
including screening for renal diseases, diabetes, colorectal
cancer, and prostate cancer, evidence-based data that show
the beneﬁt of the procedure are missing; for example, ac-
cording to a Cochrane analysis,5 mammography of 50e69-
year-old women leads to a 15% decrease in breast cancer-
associated mortality. However, every ﬁfth woman receives
a false-positive result within 10 years, the overall mortality
remains the same, and the numbers needed to screen ex-
ceeds 2,000 women. Even more doubtful is colonoscopy for
colorectal cancer screening: general acceptance is only 2e
4%, the number needed to screen is more than 862, and
correlated with a procedure-related number needed to
harm of 211. Again, the overall mortality did not change.6
Finally, screening for melanoma lacks a gold standard for
diagnosis, and conformity with histologic ﬁndings is fright-
eningly poor. Despite negligible costs for the community,
the psychological burden for the affected has not yet been
adequately addressed; again, screening does not change
overall mortality.7
In the light of these ﬁndings, how is screening for
vascular diseases to be rated?
The UK’s Department of Health recently announced a
general screening program of otherwise healthy people for
vascular diseases and diabetes called “Putting Prevention
First”. It is argued that early screening will increase the use
of preventive interventions (taking statins or antihyperten-
sives, participating in exercise, managing weight, smoking
cessation, etc.), thereby reducing the risk of vascular disease
and allowing earlier detection and treatment. The
assumption is that if applied to 15 million people aged 40e
74 years, annually the program will prevent 9,500 heart
attacks and strokes, and at least 4,000 people from devel-
oping diabetes. In addition, about 25,000 cases of diabetes
or kidney disease will be detected 1 year earlier. Screening
will be performed every 5 years, and the average annual
costs for examinations and the subsequent interventions
12 E.S. Debuswill be £332 million, with estimated savings of £3,678
million in quality-adjusted life years gained.
A major problem of most existing cardiovascular screening
programs worldwide is low compliance due to insufﬁcient
education of the public. For a screening program to be suc-
cessful, it is of the utmost importance to adhere to the
guidelines introduced by Wilson and Jungner.1 As shown by
large population-based and randomized studies, screening
for abdominal aortic aneurysms (AAAs) fulﬁlls most of these
requirements: it is cost-effective, it can be performed by
almost every family practitioner, the population at risk is well
known, and adequate therapy leads to a signiﬁcant decrease
in AAA-related mortality and even in general mortality.8e11
Although these observations strongly argue for the intro-
duction of screening programs for AAA, at present they exist
in a few countries only (Sweden, USA, UK).
The Uppsala group has reported highly interesting data in
a recent paper on carotid screening. Using an AAA screening
cohort of 65-year-old men, the authors were able to screen
97% of all invited people, which underlines the reliability of
the study population and the strength of this study. Using a
multivariate logistic regression model, they found that
smoking, hypertension, diabetes, and coronary artery dis-
ease all are independent factors for carotid atherosclerosis.
Current smoking is the strongest factor and, interestingly, as
fewer people smoke in Sweden, the prevalence of AAA is
also on the decrease. As reported in other studies, the
incidence for carotid atherosclerosis varies between 0 and
22%, and is highest when associated with three or more risk
factors.12,13 Comparisons across multiple studies are difﬁ-
cult as different deﬁnitions and screening sites are used.
However, similar to AAA, all argue for a certain beneﬁt for
carotid screening in an at-risk population.
In summary, the approach for carotid screening discussed
by this group is practical and seems to beneﬁt patients,
supporting its implementation. Nevertheless, more infor-
mation with regard to cost-effectiveness, effectiveness of
treatment, and treatment modalities for moderate and se-
vere asymptomatic carotid stenoses are needed for new
guidelines for carotid screening. This paper should
encourage us to further pursue this important issue.REFERENCES
1 Wilson JMG, Jungner G. Principles and practice of screening for
disease. Geneva: World Health Organization; 1968.
2 Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Applica-
tion of population screening principles to genetic screening for
adultonset conditions. Genet Test 2001;5:201e11.
3 Lin V, Gibson B, editors. Evidence-based health policy: problems
and possibilities. Melbourne: Oxford University Press; 2003.
4 Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria
for effective screening: their application to multislice CT
screening for pulmonary and colorectal cancers. AJR Am J
Roentgenol 2001;176:1357e62.
5 Goetzsche PC, Nielsen M. Screening for breast cancer with
mammogrpahy. Cochrane Database Syst Rev 2006;18:
CD001877.
6 Moayyedi P, Achkar E. Does fecal occult blood testing really
reduce mortality? A reanalysis of systematic review data. Am J
Gastroenterol 2006;101:380e4.
7 Edman RL, Klaus SN. Is routine screening for melanoma a
benign practice? JAMA 2000;284:883e6.
8 Ashton HA, Gao L, Kim LG, Druce PS, Thompson SG, Scott RA.
Fifteen-year follow-up of a randomized clinical trial of ultra-
sonographic screening for abdominal aortic aneurysms. Br J
Surg 2007;94:696e701.
9 Lindholt JS, Sorensen J, Sogaard R, Henneberg EW. Long-term
beneﬁt and cost-effectiveness analysis of screening for
abdominal aortic aneurysms from a randomized controlled
trial. Br J Surg 2010;97:826e34.
10 Scott RAP. The Multicentre Aneurysm Screening Study (MASS)
into the effect of abdominal aortic aneurysm screening on
mortality in men: a randomised controlled trial. Lancet
2002;360:1531e9.
11 Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT,
Spencer CA, Tuohy RJ, et al. Population based randomised
controlled trial on impact of screening on mortality from
abdominal aortic aneurysm. BMJ 2004;329:1259.
12 O’Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG,
Wolfson Jr SK, et al. Distribution and correlates of sono-
graphically detected carotid artery disease in the Cardiovas-
cular Health Study. The CHS Collaborative Research Group.
Stroke 1992;23:1752e60.
13 Mathiesen EB, Joakimsen O, Bonaa KH. Prevalence of and risk
factors associated with carotid artery stenosis: the Tromso
Study. Cerebrovasc Dis 2001;12:44e51.
